REGENXBIO’s Research and Development Facility, Maryland, US

The R&D facility is located in the Alexandria Life Science and Translational Research Center.

March 1, 2024

REGENXBIO built a research and development (R&D) facility, which it calls the Manufacturing Innovation Center, in Montgomery County in Rockville, Maryland, US.

The facility will provide the company with complete control over the entire gene therapy manufacturing process in Montgomery County. The project was announced in November 2018 and the facility was opened in June 2022.

Until December 2021, the company had allocated more than $100m towards the development of its headquarters in Rockville, which includes more than $65m invested in the Manufacturing Innovation Center located within the headquarters.

REGENXBIO’s research and development facility location

The R&D facility is located in the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive in Rockville.

The campus at 9800 Medical Center Drive currently has four buildings encompassing 282,000 rentable square feet (rsf). It exceeded approximately 460,000rsf after the completion of the new facility.

REGENXBIO entered a 15-year lease agreement with Alexandria Real Estate Equities for 132,487rsf in November 2018. It is situated close to government and regulatory authority institutions such as the National Institutes of Health and the US Food and Drug Administration.

Relocating its headquarters enables REGENXBIO to recruit a skilled workforce, form collaborations, and provide growth opportunities.